As reported in The New York Times on Dec. 7, 2010 (http://prescriptions.blogs.nytimes.com/2010/12/07/f-d-a-panel-backs-new-diet-pill/?ref=health), an F.D.A. advisory committee recommended approval of the weight loss drug, Contrave (Orexigen Therapeutics, San Diego, CA), by a voting margin of 13 to 7. While not required to do so, the F.D.A. usually follows the committee’s advice and is expected to formally approve Contrave by Jan. 31, 2011. Contrave is a combination of two currently...